Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2013, Vol. 18 ›› Issue (11): 1205-1210.

Previous Articles     Next Articles

Pharmacokinetics of Combretastatin A4 and Combretastatin A4 Phosphate in SD rats

ZHANG Xiao-lan1, WANG Zhi-qiang2, SUN Jian-guo1, PENG Ying1, ZHONG Yun-xi1, HAO Kun1, ZHANG Cang2, WANG Guang-ji1   

  1. 1Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, Jiangsu, China;
    2Drug R&D Center, Nanjing Sanhome Pharmaceutical Co.Ltd., Nanjing 210038, Jiangsu, China
  • Received:2013-02-18 Revised:2013-10-29 Online:2013-11-26 Published:2013-11-22

Abstract: AIM: An LC-MS/MS method was set up for the comparative evaluation of pharmacokinetics of CA4P and CA4 in SD rats. METHODS: 12 fasted SD rats were single intravenous administration of 50 mg/kg CA4P or 36 mg/kg CA4 (same molar amount). Plasma samples were collected at different time points and concentrations of CA4P and CA4 were analyzed by LC-MS/MS.The pharmacokinetic parameters were calculated and CA4P-CA4 transformation were simulated by pharmacokinetic model.RESULTS: After i.v. administration of 50 mg/kg CA4P or 36 mg/kg CA4, the AUC0-∞ of CA4P or CA4 were (27126±4142), (7751±801) and (5037±1433) ng·h·mL-1, respectively, the t1/2 were (0.85±0.35), (1.27±0.33) and (0.95±0.65) h, respectively. No gender differences were found in rats.CONCLUSION: The exposure of CA4 was increased significantly by soluble CA4 phosphate in SD rats. CA4P was rapidly transformed into CA4 after a single i.v. administration of CA4P in rats, according to the pharmacokinetic model of CA4P-CA4 transformation set up by us.

Key words: CA4P, CA4, LC-MS/MS, SD rat, Pharmacokinetics

CLC Number: